ClinicalTrials.gg
CompletedNCT04771273Updated Dec 3, 2024Results posted

A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3)

A Phase 2 interventional study of Survodutide and Placebo in Non-alcoholic Steatohepatitis (NASH), sponsored by Boehringer Ingelheim. Completed at 154 sites in 25 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-12-03.

Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
295
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States — 60 open to participants now, 93 under way, 13 of them phase 3. Non-alcoholic Fatty Liver Disease · United States.

Enrollment
39th of 460
295 · median 56
Started
2021
with 56 others
Phase 2
192 of 547
15 open now
Registered
379th of 547
by date

Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, this one is the 39th largest by enrollment of the 460 interventional ones that give a count, is one of 57 that started in 2021, is one of 192 in phase 2, and was the 379th registered.

Non-alcoholic Fatty Liver Disease

1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

60 of the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States are open now. Recruiting first, the newest first:

55 more — sign in →

All 60 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, or all of them as a file.
02

Study summary

This study is open for men and women with a liver disease called nonalcoholic steatohepatitis (NASH) and liver fibrosis. The purpose of the study is to find out whether a medicine called BI 456906 helps patients with NASH and liver fibrosis. The study tests 3 different doses of BI 456906 to find the dose that helps best. Participants are put into 4 groups randomly, which means by chance. There are 3 groups that each receive a different dose of BI 456906 and there is 1 group that receives placebo. BI 456906 and placebo are given as an injection under the skin once per week. The placebo injection looks like the BI 456906 injection but does not contain any medicine.

Participants are in the study for a little over 1 year (60 weeks). During this time, they visit the study site several times and have some video calls in addition. At the visits, the study doctors take different measurements. To see whether the treatment works, the doctors take a very small sample of liver tissue (biopsy) from each participant at the start and at the end of the study. They also examine the liver by ultrasound and MRI. The doctors also regularly check the general health of the participants.

03

Conditions studied

  • Non-alcoholic Steatohepatitis (NASH)
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female patients ≥ 18 years (or who are of legal age in countries where that is greater than 18 years) and ≤ 80 years of age at time of consent.
  2. Diagnosis of non-alcoholic steatohepatitis (NASH) (Non-alcoholic Fatty Liver Disease (NAFLD) Activity Score (NAS) ≥ 4, with at least 1 point in inflammation and ballooning each) and fibrosis stage F1-F3 proven by a conducted during the screening period or by a historical biopsy conducted within the last 6 months prior to randomization and stable body weight defined as less than 5% self-reported change in body weight between the historical biopsy and randomization, if a historical biopsy is used.
  3. Liver fat fraction ≥ 8% measured by Magnetic Resonance Imaging (MRI)-Proton Density Fat Fraction (PDFF) and liver stiffness > 6.0 kPa measured by FibroScan® at Visit 1 (if biopsy is scheduled during the screening period MRI-PDFF and FibroScan® assessments have to be performed prior to the biopsy). However, the diagnosis of NASH and fibrosis at liver biopsy (including historical biopsy) is the primary assessment to establish patient eligibility.
  4. Patients willing and able to undergo liver biopsies per protocol as judged by the Investigator.
  5. Signed and dated written in accordance with ICH-GCP and local legislation prior to admission to the trial.
  6. Women of (WOCBP)1 must be willing and able to use two forms of effective where at least one form is highly effective methods of birth control per International Council on Harmonisation (ICH) M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. A list of contraception methods meeting these criteria is provided in the patient information.

Further inclusion criteria apply.

Exclusion criteria

Exclusion Criteria:

  1. Current or history of significant alcohol consumption (defined as intake of > 210 g/ week in males and > 140 g/ week in females on average over a consecutive period of more than 3 months) or inability to reliably quantify alcohol consumption based on Investigator judgement within the last 5 years.
  2. Intake of medications historically associated with liver injury, hepatic steatosis or steatohepatitis within 12 weeks prior to Visit 1. Intake of restricted medications or any medications considered likely to interfere with the safe conduct of the trial.
  3. History of other forms of chronic liver disease (e.g., viral hepatitis, liver disease, primary biliary sclerosis, primary sclerosing cholangitis, Wilson's disease, hemochromatosis, Alpha-1 Antitrypsin (A1At) deficiency, history of liver transplantation). and C testing will be done at Visit 1. Patients with positive Hepatitis B surface antigen (HBsAg) should be excluded. Patients treated for must have a negative RNA test at screening and also be Hepatitis C Virus (HCV) RNA negative for at least 3 years prior to screening in order to be eligible for the trial.
  4. Suspicion, diagnosis, or history of hepatocellular carcinoma (HCC), or any documented active or suspected or history of malignancy within 5 years prior to screening, except appropriately treated basal cell carcinoma of the skin or in situ carcinoma of uterine cervix.
  5. Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, manifest hypo- or hyperthyroidism at Visit 1.
  6. History of chronic or acute pancreatitis or elevation of serum lipase/amylase > 2x or fasting serum triglyceride levels of > 500 mg/dL (> 5.65 mmol/L) at screening.
  7. Known history of (Human Immunodeficiency Virus) infection and/or tuberculosis and/or an acute COVID-19 infection at Visit 1 (confirmed by SARS CoV-2 RT-PCR test). Further exclusion criteria apply.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
295 participants (actual)

Study arms

  • Experimental
    Survodutide 2.4 mg - planned maintenance treatment

    Drug: Survodutide

  • Experimental
    Survodutide 4.8 mg - planned maintenance treatment

    Drug: Survodutide

  • Experimental
    Survodutide 6.0 mg - planned maintenance treatment

    Drug: Survodutide

  • Placebo comparator
    Placebo - planned maintenance treatment

    Drug: Placebo

Interventions

  • Survodutide

    Also known as: BI 456906

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Improvement (Yes/ no) From Baseline in Liver Histological Findings Based on Liver Biopsy After 48 Weeks of Treatment in Patients With NASH (NAS ≥ 4, Fibrosis F1-F3) - Actual Maintenance Treatment

    Percentage of patients who had an improvement from baseline in liver histological findings based on liver biopsy after 48 weeks of treatment is reported. Percentages were rounded to one decimal place. Improvement in histological findings was defined as a composite of improvement in NASH and no worsening of fibrosis. Improvement in non-alcoholic steatohepatitis (NASH) was defined as decrease of at least 2 points in non-alcoholic fatty liver disease (NAFLD) activity score (NAS) with at least 1 point decrease in NAS subscore of either lobular inflammation or ballooning. The NAS represents the sum of subscores for steatosis (scored from 0-3), lobular inflammation (scored from 0-3) and ballooning (scored from 0-2), and the total score ranges from 0 to 8 with higher scores representing worsening of the disease. The total score for the fibrosis stage ranges from 0 to 4 with higher score indication worsening of the disease. Patients without post-baseline data were considered non-responders.

    Time frame: At baseline and at 48 weeks.

  2. Improvement (Yes/ no) From Baseline in Liver Histological Findings Based on Liver Biopsy After 48 Weeks of Treatment in Patients With NASH (NAS ≥ 4, Fibrosis F1-F3) - Planned Maintenance Treatment

    Percentage of patients who had an improvement from baseline in liver histological findings based on liver biopsy after 48 weeks of treatment is reported. Percentages were rounded to one decimal place. Improvement in histological findings was defined as a composite of improvement in non-alcoholic steatohepatitis (NASH) and no worsening of fibrosis. Improvement in NASH was defined as decrease of at least 2 points in non-alcoholic fatty liver disease (NAFLD) activity score (NAS) with at least 1 point decrease in NAS subscore of either lobular inflammation or ballooning. The NAS represents the sum of subscores for steatosis (scored from 0-3), lobular inflammation (scored from 0-3) and ballooning (scored from 0-2), and the total score ranges from 0 to 8 with higher scores representing worsening of the disease. The total score for the fibrosis stage ranges from 0 to 4 with higher score indication worsening of the disease. Patients without post-baseline data were considered non-responders.

    Time frame: At baseline and after 48 weeks of treatment.

Secondary outcomes

  1. Improvement of Liver Fat Content (Yes/ no) Defined as at Least 30% Relative Reduction in Liver Fat Content After 48 Weeks of Treatment Compared to Baseline Assessed by MRI-PDFF - Actual Maintenance Treatment

    Percentage of participants with improvement in liver fat content is reported. Improvement in liver fat content was defined as percentage reduction from baseline of ≥30% in liver fat content after 48 weeks of treatment compared to baseline. Percentages were rounded to one decimal place. Liver fat content was assessed by Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF). Patients without post-baseline values were imputed as non-responders.

    Time frame: At baseline and after 48 weeks.

  2. Improvement of Liver Fat Content (Yes/ no) Defined as at Least 30% Relative Reduction in Liver Fat Content After 48 Weeks of Treatment Compared to Baseline Assessed by MRI-PDFF - Planned Maintenance Treatment

    Percentage of participants with improvement in liver fat content is reported. Improvement in liver fat content was defined as percentage reduction from baseline of ≥30% in liver fat content after 48 weeks of treatment compared to baseline. Liver fat content was assessed by Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF). Patients without post-baseline values were imputed as non-responders.

    Time frame: At baseline and at 48 weeks.

  3. Absolute Change of Liver Fat Content From Baseline After 48 Weeks of Treatment Assessed by MRI-PDFF - Actual Maintenance Treatment

    Absolute change of liver fat content (percentage \[%\]) from baseline after 48 weeks of treatment is reported. Liver fat content was assessed by Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF). Least Squares Mean (Standard error) were calculated from mixed-effect model for repeated measures (MMRM) including fixed effects for baseline liver fat content (%) as a continuous linear covariate, and treatment, presence of diabetes of any type \[yes, no\], baseline fibrosis score \[F1, F2, F3\], visit, treatment by visit interaction and baseline by visit interaction as factors.

    Time frame: MMRM included measurements from baseline and at Week 28 and at Week 48 after first drug administration. MMRM estimates of absolute change from baseline to Week 48 is reported.

  4. Absolute Change of Liver Fat Content From Baseline After 48 Weeks of Treatment Assessed by MRI-PDFF - Planned Maintenance Treatment

    Absolute change of liver fat content from baseline after 48 weeks of treatment is reported. Liver fat content was assessed by Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF). Least Squares Mean (Standard error) were calculated from mixed-effect model for repeated measures (MMRM) including fixed effects for baseline liver fat content (%) as a continuous linear covariate, and treatment, presence of diabetes of any type \[yes, no\], baseline fibrosis score \[F1, F2, F3\], visit, treatment by visit interaction and baseline by visit interaction as factors.

    Time frame: MMRM included measurements from baseline and at Week 28 and at Week 48 after first drug administration. MMRM estimates of absolute change from baseline to Week 48 is reported.

  5. Percent Change of Liver Fat Content From Baseline After 48 Weeks of Treatment Assessed by MRI-PDFF - Actual Maintenance Treatment

    Percent change of liver fat content (percentage \[%\]) from baseline after 48 weeks of treatment is reported. Liver fat content was assessed by Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF). Least Squares Mean (Standard error) were calculated from mixed-effect model for repeated measures (MMRM) including fixed effects for baseline liver fat content (%) as a continuous linear covariate, and treatment, presence of diabetes of any type \[yes, no\], baseline fibrosis score \[F1, F2, F3\], visit, treatment by visit interaction and baseline by visit interaction as factors.

    Time frame: MMRM included measurements from baseline and at Week 28 and at Week 48 after first drug administration. MMRM estimates of percent change from baseline to Week 48 is reported.

  6. Percent Change of Liver Fat Content From Baseline After 48 Weeks of Treatment Assessed by MRI-PDFF - Planned Maintenance Treatment

    Percent change of liver fat content (percentage \[%\]) from baseline after 48 weeks of treatment is reported. Liver fat content was assessed by Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF). Least Squares Mean (Standard error) were calculated from mixed-effect model for repeated measures (MMRM) including fixed effects for baseline liver fat content (%) as a continuous linear covariate, and treatment, presence of diabetes of any type \[yes, no\], baseline fibrosis score \[F1, F2, F3\], visit, treatment by visit interaction and baseline by visit interaction as factors.

    Time frame: MMRM included measurements from baseline and at Week 28 and at Week 48 after first drug administration. MMRM estimates of percent change from baseline to Week 48 is reported.

  7. Improvement of Fibrosis (Yes/ no) Defined as at Least One Stage Decrease in Fibrosis Stage After 48 Weeks of Treatment Assessed by Liver Biopsy - Actual Maintenance Treatment

    Percentage of participants with improvement of liver fibrosis is reported. Improvement of fibrosis was defined as at least one stage decrease in fibrosis stage after 48 weeks of treatment assessed by liver biopsy. The total score for the fibrosis stage ranges from 0 to 4 with higher score indication worsening of the disease and the stages of fibrosis based on their location are the following: * 1A Zone 3, perisinusoidal, delicate; * 1B Zone 3, perisinusoidal, dense; * 1C Portal, periportal only; * 2 Zone 3, perisinusoidal + portal, periportal only; * 3 Bridging fibrosis; * 4 Cirrhosis. For analysis purposes no distinction was made between stages 1A, 1B and 1C.

    Time frame: At baseline and after 48 weeks of treatment.

  8. Improvement of Fibrosis (Yes/ no) Defined as at Least One Stage Decrease in Fibrosis Stage After 48 Weeks of Treatment Assessed by Liver Biopsy - Planned Maintenance Treatment

    Percentage of participants with improvement of liver fibrosis is reported. Improvement of fibrosis was defined as at least one stage decrease in fibrosis stage after 48 weeks of treatment assessed by liver biopsy. The total score for the fibrosis stage ranges from 0 to 4 with higher score indication worsening of the disease and the stages of fibrosis based on their location are the following: * 1A Zone 3, perisinusoidal, delicate; * 1B Zone 3, perisinusoidal, dense; * 1C Portal, periportal only; * 2 Zone 3, perisinusoidal + portal, periportal only; * 3 Bridging fibrosis; * 4 Cirrhosis. For analysis purposes no distinction was made between stages 1A, 1B and 1C.

    Time frame: At baseline and after 48 weeks of treatment.

  9. Absolute Change From Baseline in NAS After 48 Weeks of Treatment Assessed by Liver Biopsy - Actual Maintenance Treatment

    Absolute change from baseline in NAS after 48 weeks of treatment assessed by liver biopsy is reported. The non-alcoholic fatty liver disease (NAFLD) activity score (NAS) represents the sum of subscores for steatosis (scored from 0-3), lobular inflammation (scored from 0-3) and ballooning (scored from 0-2), and the total score ranges from 0 to 8 with higher scores representing worsening of the disease.

    Time frame: At baseline and 48 weeks of treatment.

  10. Absolute Change From Baseline in NAS After 48 Weeks of Treatment Assessed by Liver Biopsy - Planned Maintenance Treatment

    Absolute change from baseline in NAS after 48 weeks of treatment assessed by liver biopsy is reported. The non-alcoholic fatty liver disease (NAFLD) activity score (NAS) represents the sum of subscores for steatosis (scored from 0-3), lobular inflammation (scored from 0-3) and ballooning (scored from 0-2), and the total score ranges from 0 to 8 with higher scores representing worsening of the disease.

    Time frame: At baseline and 48 weeks of treatment.

07

Results

Posted Dec 3, 2024

Participant flow

This was a 48 weeks, multi-centre, randomised, dose-ranging, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy, safety and tolerability of multiple subcutaneous (s.c.) doses of survodutide (BI 456906) in patients with non-alcoholic steatohepatitis (NASH). Main parameters for inclusion of patients and for evaluation of treatment response were based on the histological evaluation from the liver biopsy and non-invasive imaging modalities.

Dose Escalation Period
Participant flow — Dose Escalation Period
MilestoneSurvodutide 2.4 mg - Planned Maintenance TreatmentSurvodutide 4.8 mg - Planned Maintenance TreatmentSurvodutide 6.0 mg - Planned Maintenance TreatmentPlacebo - Planned Maintenance Treatment
Started73737574
Treated with trial medication73727474
Completed62635768
Not completed1110186
Withdrew: Not treated with trial medication0110
Withdrew: Other reasons than listed2021
Withdrew: Protocol violation0031
Withdrew: Burden of study procedures1000
Withdrew: Change of residence0001
Withdrew: Perceived lack of efficacy0001
Withdrew: Adverse event89122
Maintenance Period
Participant flow — Maintenance Period
MilestoneSurvodutide 2.4 mg - Planned Maintenance TreatmentSurvodutide 4.8 mg - Planned Maintenance TreatmentSurvodutide 6.0 mg - Planned Maintenance TreatmentPlacebo - Planned Maintenance Treatment
Started62635768
Completed53554964
Not completed9884
Withdrew: Other than listed4203
Withdrew: Burden of study procedures1000
Withdrew: Change of residence0130
Withdrew: Perceived lack of efficacy0001
Withdrew: Adverse event4550

Outcome measures

PrimaryImprovement (Yes/ no) From Baseline in Liver Histological Findings Based on Liver Biopsy After 48 Weeks of Treatment in Patients With NASH (NAS ≥ 4, Fibrosis F1-F3) - Actual Maintenance Treatment

Percentage of patients who had an improvement from baseline in liver histological findings based on liver biopsy after 48 weeks of treatment is reported. Percentages were rounded to one decimal place. Improvement in histological findings was defined as a composite of improvement in NASH and no worsening of fibrosis. Improvement in non-alcoholic steatohepatitis (NASH) was defined as decrease of at least 2 points in non-alcoholic fatty liver disease (NAFLD) activity score (NAS) with at least 1 point decrease in NAS subscore of either lobular inflammation or ballooning. The NAS represents the sum of subscores for steatosis (scored from 0-3), lobular inflammation (scored from 0-3) and ballooning (scored from 0-2), and the total score ranges from 0 to 8 with higher scores representing worsening of the disease. The total score for the fibrosis stage ranges from 0 to 4 with higher score indication worsening of the disease. Patients without post-baseline data were considered non-responders.

Time frame:
At baseline and at 48 weeks.
Reported as:
Number · Percentage of participants
Improvement (Yes/ no) From Baseline in Liver Histological Findings Based on Liver Biopsy After 48 Weeks of Treatment in Patients With NASH (NAS ≥ 4, Fibrosis F1-F3) - Actual Maintenance Treatment
Percentage of participantsSurvodutide 2.4 mg - Actual Maintenance TreatmentSurvodutide 4.8 mg - Actual Maintenance TreatmentSurvodutide 6.0 mg - Actual Maintenance TreatmentPlacebo - Actual Maintenance Treatment
Improvement (Yes/ no) From Baseline in Liver Histological Findings Based on Liver Biopsy After 48 Weeks of Treatment in Patients With NASH (NAS ≥ 4, Fibrosis F1-F3) - Actual Maintenance Treatment38.763.855.815.2
Statistical analysis
  • Survodutide 2.4 mg - Actual Maintenance Treatment vs Placebo - Actual Maintenance Treatment · Regression, Logistic · p = 0.0010 (The p-value reported is considered nominal.) · Odds ratio (or): 3.47 · 95% CI 1.66 to 7.25Survodutide 2.4 mg vs. Placebo
  • Survodutide 4.8 mg - Actual Maintenance Treatment vs Placebo - Actual Maintenance Treatment · Regression, Logistic · p = <0.0001 (The p-value reported is considered nominal.) · Odds ratio (or): 9.52 · 95% CI 4.35 to 20.85Survodutide 4.8 mg vs. Placebo
  • Survodutide 6.0 mg - Actual Maintenance Treatment vs Placebo - Actual Maintenance Treatment · Regression, Logistic · p = <.0001 (The p-value reported is considered nominal.) · Odds ratio (or): 7.07 · 95% CI 3.10 to 16.16
  • Survodutide 2.4 mg - Actual Maintenance Treatment vs Survodutide 4.8 mg - Actual Maintenance Treatment vs Survodutide 6.0 mg - Actual Maintenance Treatment vs Placebo - Actual Maintenance Treatment · MCP-Mod linear model fit · p = <0.0001Linear model fit assumption
  • Survodutide 2.4 mg - Actual Maintenance Treatment vs Survodutide 4.8 mg - Actual Maintenance Treatment vs Survodutide 6.0 mg - Actual Maintenance Treatment vs Placebo - Actual Maintenance Treatment · MCP-Mod exponential-1 model fit · p = <0.0001Model assumption: 25% of maximum effect is achieved at dose 3.0 mg.
  • Survodutide 2.4 mg - Actual Maintenance Treatment vs Survodutide 4.8 mg - Actual Maintenance Treatment vs Survodutide 6.0 mg - Actual Maintenance Treatment vs Placebo - Actual Maintenance Treatment · MCP-Mod exponential -2 model fit · p = 0.0008Model assumption: 5% of maximum effect is achieved at dose 3.0 mg.
  • Survodutide 2.4 mg - Actual Maintenance Treatment vs Survodutide 4.8 mg - Actual Maintenance Treatment vs Survodutide 6.0 mg - Actual Maintenance Treatment vs Placebo - Actual Maintenance Treatment · MCP-Mod Emax1 model fit · p = <0.0001Model assumption: 50% of maximum effect is achieved at dose 3.0 mg.
  • Survodutide 2.4 mg - Actual Maintenance Treatment vs Survodutide 4.8 mg - Actual Maintenance Treatment vs Survodutide 6.0 mg - Actual Maintenance Treatment vs Placebo - Actual Maintenance Treatment · MCP-Mod Emax2 model fit · p = <0.0001Model assumption: 80% of maximum effect is achieved at dose 3.0 mg.
  • Survodutide 2.4 mg - Actual Maintenance Treatment vs Survodutide 4.8 mg - Actual Maintenance Treatment vs Survodutide 6.0 mg - Actual Maintenance Treatment vs Placebo - Actual Maintenance Treatment · MCP-Mod quadratic model fit · p = <0.0001Model assumption: Maximum effect is achieved at dose 4.8 mg.
PrimaryImprovement (Yes/ no) From Baseline in Liver Histological Findings Based on Liver Biopsy After 48 Weeks of Treatment in Patients With NASH (NAS ≥ 4, Fibrosis F1-F3) - Planned Maintenance Treatment

Percentage of patients who had an improvement from baseline in liver histological findings based on liver biopsy after 48 weeks of treatment is reported. Percentages were rounded to one decimal place. Improvement in histological findings was defined as a composite of improvement in non-alcoholic steatohepatitis (NASH) and no worsening of fibrosis. Improvement in NASH was defined as decrease of at least 2 points in non-alcoholic fatty liver disease (NAFLD) activity score (NAS) with at least 1 point decrease in NAS subscore of either lobular inflammation or ballooning. The NAS represents the sum of subscores for steatosis (scored from 0-3), lobular inflammation (scored from 0-3) and ballooning (scored from 0-2), and the total score ranges from 0 to 8 with higher scores representing worsening of the disease. The total score for the fibrosis stage ranges from 0 to 4 with higher score indication worsening of the disease. Patients without post-baseline data were considered non-responders.

Time frame:
At baseline and after 48 weeks of treatment.
Reported as:
Number · percentage of participants
Improvement (Yes/ no) From Baseline in Liver Histological Findings Based on Liver Biopsy After 48 Weeks of Treatment in Patients With NASH (NAS ≥ 4, Fibrosis F1-F3) - Planned Maintenance Treatment
percentage of participantsSurvodutide 2.4 mg - Planned Maintenance TreatmentSurvodutide 4.8 mg - Planned Maintenance TreatmentSurvodutide 6.0 mg - Planned Maintenance TreatmentPlacebo - Planned Maintenance Treatment
Improvement (Yes/ no) From Baseline in Liver Histological Findings Based on Liver Biopsy After 48 Weeks of Treatment in Patients With NASH (NAS ≥ 4, Fibrosis F1-F3) - Planned Maintenance Treatment46.662.543.213.5
Statistical analysis
  • Survodutide 2.4 mg - Planned Maintenance Treatment vs Placebo - Planned Maintenance Treatment · Regression, Logistic · p = <.0001 (The p-value reported is considered nominal.) · Odds ratio (or): 5.49 · 95% CI 2.46 to 12.28Survodutide 2.4 mg vs. Placebo
  • Survodutide 4.8 mg - Planned Maintenance Treatment vs Placebo - Planned Maintenance Treatment · Regression, Logistic · p = <.0001 (The p-value reported is considered nominal.) · Odds ratio (or): 10.14 · 95% CI 4.49 to 22.87Survodutide 4.8 mg vs. Placebo
  • Survodutide 6.0 mg - Planned Maintenance Treatment vs Placebo - Planned Maintenance Treatment · Regression, Logistic · p = 0.0001 (The p-value reported is considered nominal.) · Odds ratio (or): 4.87 · 95% CI 2.18 to 10.91Survodutide 6.0 mg vs. Placebo
  • Survodutide 2.4 mg - Planned Maintenance Treatment vs Survodutide 4.8 mg - Planned Maintenance Treatment vs Survodutide 6.0 mg - Planned Maintenance Treatment vs Placebo - Planned Maintenance Treatment · MCPMod linear model fit · p = 0.0001linear model fit assumption
  • Survodutide 2.4 mg - Planned Maintenance Treatment vs Survodutide 4.8 mg - Planned Maintenance Treatment vs Survodutide 6.0 mg - Planned Maintenance Treatment vs Placebo - Planned Maintenance Treatment · MCPMod exponential-1 model fit · p = 0.0115Model assumption: 25% of maximum effect is achieved at dose 3.0 mg.
  • Survodutide 2.4 mg - Planned Maintenance Treatment vs Survodutide 4.8 mg - Planned Maintenance Treatment vs Survodutide 6.0 mg - Planned Maintenance Treatment vs Placebo - Planned Maintenance Treatment · MCP-Mod exponential-2 model fit · p = 0.2204Model assumption: 5% of maximum effect is achieved at dose 3.0 mg.
  • Survodutide 2.4 mg - Planned Maintenance Treatment vs Survodutide 4.8 mg - Planned Maintenance Treatment vs Survodutide 6.0 mg - Planned Maintenance Treatment vs Placebo - Planned Maintenance Treatment · MCP-Mod Emax1 model fit · p = <0.0001Model assumption: 50% of maximum effect is achieved at dose 3.0 mg.
  • Survodutide 2.4 mg - Planned Maintenance Treatment vs Survodutide 4.8 mg - Planned Maintenance Treatment vs Survodutide 6.0 mg - Planned Maintenance Treatment vs Placebo - Planned Maintenance Treatment · MCP-Mod Emax2 · p = <0.0001Model assumption: 80% of maximum effect is achieved at dose 3.0 mg.
  • Survodutide 2.4 mg - Planned Maintenance Treatment vs Survodutide 4.8 mg - Planned Maintenance Treatment vs Survodutide 6.0 mg - Planned Maintenance Treatment vs Placebo - Planned Maintenance Treatment · MCP-Mod quadratic model fit · p = <0.0001Model assumption: Maximum effect is achieved at dose 4.8 mg.
SecondaryImprovement of Liver Fat Content (Yes/ no) Defined as at Least 30% Relative Reduction in Liver Fat Content After 48 Weeks of Treatment Compared to Baseline Assessed by MRI-PDFF - Actual Maintenance Treatment

Percentage of participants with improvement in liver fat content is reported. Improvement in liver fat content was defined as percentage reduction from baseline of ≥30% in liver fat content after 48 weeks of treatment compared to baseline. Percentages were rounded to one decimal place. Liver fat content was assessed by Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF). Patients without post-baseline values were imputed as non-responders.

Time frame:
At baseline and after 48 weeks.
Reported as:
Number · Percentage of participants
Improvement of Liver Fat Content (Yes/ no) Defined as at Least 30% Relative Reduction in Liver Fat Content After 48 Weeks of Treatment Compared to Baseline Assessed by MRI-PDFF - Actual Maintenance Treatment
Percentage of participantsSurvodutide 2.4 mg - Actual Maintenance TreatmentSurvodutide 4.8 mg - Actual Maintenance TreatmentSurvodutide 6.0 mg - Actual Maintenance TreatmentPlacebo - Actual Maintenance Treatment
Improvement of Liver Fat Content (Yes/ no) Defined as at Least 30% Relative Reduction in Liver Fat Content After 48 Weeks of Treatment Compared to Baseline Assessed by MRI-PDFF - Actual Maintenance Treatment50.566.776.916.5
Statistical analysis
  • Survodutide 2.4 mg - Actual Maintenance Treatment vs Placebo - Actual Maintenance Treatment · Regression, Logistic · p = <.0001 (The p-value reported is considered nominal.) · Odds ratio (or): 5.07 · 95% CI 2.47 to 10.40Survodutide 2.4 mg vs. Placebo
  • Survodutide 4.8 mg - Actual Maintenance Treatment vs Placebo - Actual Maintenance Treatment · Regression, Logistic · p = <.0001 (The p-value reported is considered nominal.) · Odds ratio (or): 9.46 · 95% CI 4.36 to 20.51Survodutide 4.8 mg vs. Placebo
  • Survodutide 6.0 mg - Actual Maintenance Treatment vs Placebo - Actual Maintenance Treatment · Regression, Logistic · p = <.0001 (The p-value reported is considered nominal.) · Odds ratio (or): 16.09 · 95% CI 6.69 to 38.73Survodutide 6.0 mg vs. Placebo
  • Survodutide 2.4 mg - Actual Maintenance Treatment vs Survodutide 4.8 mg - Actual Maintenance Treatment vs Survodutide 6.0 mg - Actual Maintenance Treatment vs Placebo - Actual Maintenance Treatment · MCP-Mod linear model fit · p = <0.0001Linear model fit assumption
  • Survodutide 2.4 mg - Actual Maintenance Treatment vs Survodutide 4.8 mg - Actual Maintenance Treatment vs Survodutide 6.0 mg - Actual Maintenance Treatment vs Placebo - Actual Maintenance Treatment · MCP-Mod exponential-1 model fit · p = <0.0001Model assumption: 25% of maximum effect is achieved at dose 3.0 mg.
  • Survodutide 2.4 mg - Actual Maintenance Treatment vs Survodutide 4.8 mg - Actual Maintenance Treatment vs Survodutide 6.0 mg - Actual Maintenance Treatment vs Placebo - Actual Maintenance Treatment · MCP-Mod exponential-2 model fit · p = <0.0001Model assumption: 5% of maximum effect achieved at dose 3.0 mg.
  • Survodutide 2.4 mg - Actual Maintenance Treatment vs Survodutide 4.8 mg - Actual Maintenance Treatment vs Survodutide 6.0 mg - Actual Maintenance Treatment vs Placebo - Actual Maintenance Treatment · MCP-Mod Emax1 model fit · p = <0.0001Model assumption: 50% of maximum effect is achieved at dose 3.0 mg.
  • Survodutide 2.4 mg - Actual Maintenance Treatment vs Survodutide 4.8 mg - Actual Maintenance Treatment vs Survodutide 6.0 mg - Actual Maintenance Treatment vs Placebo - Actual Maintenance Treatment · MCP-Mod Emax2 model fit · p = <0.0001Model assumption: 80% of maximum effect is achieved at dose 3.0 mg.
  • Survodutide 2.4 mg - Actual Maintenance Treatment vs Survodutide 4.8 mg - Actual Maintenance Treatment vs Survodutide 6.0 mg - Actual Maintenance Treatment vs Placebo - Actual Maintenance Treatment · MCP-Mod quadratic model fit · p = <0.0001Model assumption: Maximum effect is achieved at dose 4.8 mg.
SecondaryImprovement of Liver Fat Content (Yes/ no) Defined as at Least 30% Relative Reduction in Liver Fat Content After 48 Weeks of Treatment Compared to Baseline Assessed by MRI-PDFF - Planned Maintenance Treatment

Percentage of participants with improvement in liver fat content is reported. Improvement in liver fat content was defined as percentage reduction from baseline of ≥30% in liver fat content after 48 weeks of treatment compared to baseline. Liver fat content was assessed by Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF). Patients without post-baseline values were imputed as non-responders.

Time frame:
At baseline and at 48 weeks.
Reported as:
Number · Percentage of participants
Improvement of Liver Fat Content (Yes/ no) Defined as at Least 30% Relative Reduction in Liver Fat Content After 48 Weeks of Treatment Compared to Baseline Assessed by MRI-PDFF - Planned Maintenance Treatment
Percentage of participantsSurvodutide 2.4 mg - Planned Maintenance TreatmentSurvodutide 4.8 mg - Planned Maintenance TreatmentSurvodutide 6.0 mg - Planned Maintenance TreatmentPlacebo - Planned Maintenance Treatment
Improvement of Liver Fat Content (Yes/ no) Defined as at Least 30% Relative Reduction in Liver Fat Content After 48 Weeks of Treatment Compared to Baseline Assessed by MRI-PDFF - Planned Maintenance Treatment63.066.756.813.5
Statistical analysis
  • Survodutide 2.4 mg - Planned Maintenance Treatment vs Placebo - Planned Maintenance Treatment · Regression, Logistic · p = <.0001 (The p-value reported is considered nominal.) · Odds ratio (or): 10.39 · 95% CI 4.60 to 23.45Survodutide 2.4 mg vs. Placebo
  • Survodutide 4.8 mg - Planned Maintenance Treatment vs Placebo - Planned Maintenance Treatment · Regression, Logistic · p = <.0001 (The p-value reported is considered nominal.) · Odds ratio (or): 12.06 · 95% CI 5.30 to 27.45Survodutide 4.8 mg vs. Placebo
  • Survodutide 6.0 mg - Planned Maintenance Treatment vs Placebo - Planned Maintenance Treatment · Regression, Logistic · p = <.0001 (The p-value reported is considered nominal.) · Odds ratio (or): 8.22 · 95% CI 3.66 to 18.50Survodutide 6.0 mg vs. Placebo
  • Survodutide 2.4 mg - Planned Maintenance Treatment vs Survodutide 4.8 mg - Planned Maintenance Treatment vs Survodutide 6.0 mg - Planned Maintenance Treatment vs Placebo - Planned Maintenance Treatment · MCP-Mod linear model fit · p = <0.0001Linear model fit assumption.
  • Survodutide 2.4 mg - Planned Maintenance Treatment vs Survodutide 4.8 mg - Planned Maintenance Treatment vs Survodutide 6.0 mg - Planned Maintenance Treatment vs Placebo - Planned Maintenance Treatment · MCP-Mod exponential-1 model fit · p = 0.0031Model assumption: 25% of maximum effect is achieved at dose 3.0 mg.
  • Survodutide 2.4 mg - Planned Maintenance Treatment vs Survodutide 4.8 mg - Planned Maintenance Treatment vs Survodutide 6.0 mg - Planned Maintenance Treatment vs Placebo - Planned Maintenance Treatment · MCP-Mod exponential-2 model fit · p = 0.0925Model assumption: 5% of maximum effect is achieved at dose 3.0 mg.
  • Survodutide 2.4 mg - Planned Maintenance Treatment vs Survodutide 4.8 mg - Planned Maintenance Treatment vs Survodutide 6.0 mg - Planned Maintenance Treatment vs Placebo - Planned Maintenance Treatment · MCP-Mod Emax1 model fit · p = <0.0001Model assumption: 50% of maximum effect is achieved at dose 3.0 mg.
  • Survodutide 2.4 mg - Planned Maintenance Treatment vs Survodutide 4.8 mg - Planned Maintenance Treatment vs Survodutide 6.0 mg - Planned Maintenance Treatment vs Placebo - Planned Maintenance Treatment · MCP-Mod Emax2 model fit · p = <0.0001Model assumption: 80% of maximum effect is achieved at dose 3.0 mg.
  • Survodutide 2.4 mg - Planned Maintenance Treatment vs Survodutide 4.8 mg - Planned Maintenance Treatment vs Survodutide 6.0 mg - Planned Maintenance Treatment vs Placebo - Planned Maintenance Treatment · MCP-Mod quadratic model fit · p = <0.0001Model assumption: Maximum effect is achieved at dose 4.8 mg.
SecondaryAbsolute Change of Liver Fat Content From Baseline After 48 Weeks of Treatment Assessed by MRI-PDFF - Actual Maintenance Treatment

Absolute change of liver fat content (percentage \[%\]) from baseline after 48 weeks of treatment is reported. Liver fat content was assessed by Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF). Least Squares Mean (Standard error) were calculated from mixed-effect model for repeated measures (MMRM) including fixed effects for baseline liver fat content (%) as a continuous linear covariate, and treatment, presence of diabetes of any type \[yes, no\], baseline fibrosis score \[F1, F2, F3\], visit, treatment by visit interaction and baseline by visit interaction as factors.

Time frame:
MMRM included measurements from baseline and at Week 28 and at Week 48 after first drug administration. MMRM estimates of absolute change from baseline to Week 48 is reported.
Reported as:
Least squares mean · percentage of liver fat content
Absolute Change of Liver Fat Content From Baseline After 48 Weeks of Treatment Assessed by MRI-PDFF - Actual Maintenance Treatment
percentage of liver fat contentSurvodutide 2.4 mg - Actual Maintenance TreatmentSurvodutide 4.8 mg - Actual Maintenance TreatmentSurvodutide 6.0 mg - Actual Maintenance TreatmentPlacebo - Actual Maintenance Treatment
Absolute Change of Liver Fat Content From Baseline After 48 Weeks of Treatment Assessed by MRI-PDFF - Actual Maintenance Treatment-10.48 (-11.92 to -9.04)-12.80 (-14.32 to -11.28)-12.96 (-14.62 to -11.30)-1.89 (-3.26 to -0.51)
Statistical analysis
  • Survodutide 2.4 mg - Actual Maintenance Treatment vs Placebo - Actual Maintenance Treatment · MMRM · p = <.0001 (The p-value reported is considered nominal.) · Mean difference (net): -8.59 · 95% CI -10.59 to -6.60"Survodutide 2.4 mg" - "Placebo".
  • Survodutide 4.8 mg - Actual Maintenance Treatment vs Placebo - Actual Maintenance Treatment · MMRM · p = <.0001 (The p-value reported is considered nominal.) · Mean difference (net): -10.91 · 95% CI -12.96 to -8.86"Survodutide 4.8 mg" - "Placebo".
  • Survodutide 6.0 mg - Actual Maintenance Treatment vs Placebo - Actual Maintenance Treatment · MMRM · p = <.0001 (The p-value reported is considered nominal.) · Mean difference (net): -11.07 · 95% CI -13.23 to -8.92"Survodutide 6.0 mg" - "Placebo".
SecondaryAbsolute Change of Liver Fat Content From Baseline After 48 Weeks of Treatment Assessed by MRI-PDFF - Planned Maintenance Treatment

Absolute change of liver fat content from baseline after 48 weeks of treatment is reported. Liver fat content was assessed by Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF). Least Squares Mean (Standard error) were calculated from mixed-effect model for repeated measures (MMRM) including fixed effects for baseline liver fat content (%) as a continuous linear covariate, and treatment, presence of diabetes of any type \[yes, no\], baseline fibrosis score \[F1, F2, F3\], visit, treatment by visit interaction and baseline by visit interaction as factors.

Time frame:
MMRM included measurements from baseline and at Week 28 and at Week 48 after first drug administration. MMRM estimates of absolute change from baseline to Week 48 is reported.
Reported as:
Least squares mean · percentage of liver fat content
Absolute Change of Liver Fat Content From Baseline After 48 Weeks of Treatment Assessed by MRI-PDFF - Planned Maintenance Treatment
percentage of liver fat contentSurvodutide 2.4 mg - Planned Maintenance TreatmentSurvodutide 4.8 mg - Planned Maintenance TreatmentSurvodutide 6.0 mg - Planned Maintenance TreatmentPlacebo - Planned Maintenance Treatment
Absolute Change of Liver Fat Content From Baseline After 48 Weeks of Treatment Assessed by MRI-PDFF - Planned Maintenance Treatment-10.73 (-12.25 to -9.22)-12.40 (-13.90 to -10.91)-12.48 (-14.06 to -10.89)-1.61 (-3.04 to -0.19)
Statistical analysis
  • Survodutide 2.4 mg - Planned Maintenance Treatment vs Placebo - Planned Maintenance Treatment · MMRM · p = <.0001 (The p-value reported is considered nominal.) · Mean difference (net): -9.12 · 95% CI -11.21 to -7.03"Survodutide 2.4 mg" - "Placebo".
  • Survodutide 4.8 mg - Planned Maintenance Treatment vs Placebo - Planned Maintenance Treatment · MMRM · p = <.0001 (The p-value reported is considered nominal.) · Mean difference (net): -10.79 · 95% CI -12.85 to -8.73"Survodutide 4.8 mg" - "Placebo".
  • Survodutide 6.0 mg - Planned Maintenance Treatment vs Placebo - Planned Maintenance Treatment · MMRM · p = <.0001 (The p-value reported is considered nominal.) · Mean difference (net): -10.86 · 95% CI -13.00 to -8.73"Survodutide 6.0 mg" - "Placebo".
SecondaryPercent Change of Liver Fat Content From Baseline After 48 Weeks of Treatment Assessed by MRI-PDFF - Actual Maintenance Treatment

Percent change of liver fat content (percentage \[%\]) from baseline after 48 weeks of treatment is reported. Liver fat content was assessed by Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF). Least Squares Mean (Standard error) were calculated from mixed-effect model for repeated measures (MMRM) including fixed effects for baseline liver fat content (%) as a continuous linear covariate, and treatment, presence of diabetes of any type \[yes, no\], baseline fibrosis score \[F1, F2, F3\], visit, treatment by visit interaction and baseline by visit interaction as factors.

Time frame:
MMRM included measurements from baseline and at Week 28 and at Week 48 after first drug administration. MMRM estimates of percent change from baseline to Week 48 is reported.
Reported as:
Least squares mean · percent change of liver fat content
Percent Change of Liver Fat Content From Baseline After 48 Weeks of Treatment Assessed by MRI-PDFF - Actual Maintenance Treatment
percent change of liver fat contentSurvodutide 2.4 mg - Actual Maintenance TreatmentSurvodutide 4.8 mg - Actual Maintenance TreatmentSurvodutide 6.0 mg - Actual Maintenance TreatmentPlacebo - Actual Maintenance Treatment
Percent Change of Liver Fat Content From Baseline After 48 Weeks of Treatment Assessed by MRI-PDFF - Actual Maintenance Treatment-50.92 (-58.05 to -43.80)-62.79 (-70.26 to -55.32)-64.30 (-72.48 to -56.12)-7.28 (-14.06 to -0.50)
Statistical analysis
  • Survodutide 2.4 mg - Actual Maintenance Treatment vs Placebo - Actual Maintenance Treatment · MMRM · p = <.0001 (The p-value reported is considered nominal.) · Mean difference (net): -43.64 · 95% CI -53.49 to -33.79"Survodutide 2.4 mg" - "Placebo"
  • Survodutide 4.8 mg - Actual Maintenance Treatment vs Placebo - Actual Maintenance Treatment · MMRM · p = <.0001 (The p-value reported is considered nominal.) · Mean difference (net): -55.52 · 95% CI -65.61 to -45.42"Survodutide 4.8 mg" - "Placebo"
  • Survodutide 6.0 mg - Actual Maintenance Treatment vs Placebo - Actual Maintenance Treatment · MMRM · p = <.0001 (The p-value reported is considered nominal.) · Mean difference (net): -57.02 · 95% CI -67.66 to -46.39"Survodutide 6.0 mg"-"Placebo"
SecondaryPercent Change of Liver Fat Content From Baseline After 48 Weeks of Treatment Assessed by MRI-PDFF - Planned Maintenance Treatment

Percent change of liver fat content (percentage \[%\]) from baseline after 48 weeks of treatment is reported. Liver fat content was assessed by Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF). Least Squares Mean (Standard error) were calculated from mixed-effect model for repeated measures (MMRM) including fixed effects for baseline liver fat content (%) as a continuous linear covariate, and treatment, presence of diabetes of any type \[yes, no\], baseline fibrosis score \[F1, F2, F3\], visit, treatment by visit interaction and baseline by visit interaction as factors.

Time frame:
MMRM included measurements from baseline and at Week 28 and at Week 48 after first drug administration. MMRM estimates of percent change from baseline to Week 48 is reported.
Reported as:
Least squares mean · percent change of liver fat content
Percent Change of Liver Fat Content From Baseline After 48 Weeks of Treatment Assessed by MRI-PDFF - Planned Maintenance Treatment
percent change of liver fat contentSurvodutide 2.4 mg - Planned Maintenance TreatmentSurvodutide 4.8 mg - Planned Maintenance TreatmentSurvodutide 6.0 mg - Planned Maintenance TreatmentPlacebo - Planned Maintenance Treatment
Percent Change of Liver Fat Content From Baseline After 48 Weeks of Treatment Assessed by MRI-PDFF - Planned Maintenance Treatment-52.20 (-59.66 to -44.75)-60.82 (-68.16 to -53.48)-61.97 (-69.78 to -54.16)-5.71 (-12.70 to 1.28)
Statistical analysis
  • Survodutide 2.4 mg - Planned Maintenance Treatment vs Placebo - Planned Maintenance Treatment · MMRM · p = <.0001 (The p-value reported is considered nominal.) · Mean difference (net): -46.49 · 95% CI -56.74 to -36.25"Survodutide 2.4 mg" - "Placebo"
  • Survodutide 4.8 mg - Planned Maintenance Treatment vs Placebo - Planned Maintenance Treatment · MMRM · p = <.0001 (The p-value reported is considered nominal.) · Mean difference (net): -55.11 · 95% CI -65.25 to -44.98"Survodutide 4.8 mg" - "Placebo"
  • Survodutide 6.0 mg - Planned Maintenance Treatment vs Placebo - Planned Maintenance Treatment · MMRM · p = <.0001 (The p-value reported is considered nominal.) · Mean difference (net): -56.26 · 95% CI -66.76 to -45.77"Survodutide 6.0 mg"-"Placebo"
SecondaryImprovement of Fibrosis (Yes/ no) Defined as at Least One Stage Decrease in Fibrosis Stage After 48 Weeks of Treatment Assessed by Liver Biopsy - Actual Maintenance Treatment

Percentage of participants with improvement of liver fibrosis is reported. Improvement of fibrosis was defined as at least one stage decrease in fibrosis stage after 48 weeks of treatment assessed by liver biopsy. The total score for the fibrosis stage ranges from 0 to 4 with higher score indication worsening of the disease and the stages of fibrosis based on their location are the following: * 1A Zone 3, perisinusoidal, delicate; * 1B Zone 3, perisinusoidal, dense; * 1C Portal, periportal only; * 2 Zone 3, perisinusoidal + portal, periportal only; * 3 Bridging fibrosis; * 4 Cirrhosis. For analysis purposes no distinction was made between stages 1A, 1B and 1C.

Time frame:
At baseline and after 48 weeks of treatment.
Reported as:
Number · Percentage of participants
Improvement of Fibrosis (Yes/ no) Defined as at Least One Stage Decrease in Fibrosis Stage After 48 Weeks of Treatment Assessed by Liver Biopsy - Actual Maintenance Treatment
Percentage of participantsSurvodutide 2.4 mg - Actual Maintenance TreatmentSurvodutide 4.8 mg - Actual Maintenance TreatmentSurvodutide 6.0 mg - Actual Maintenance TreatmentPlacebo - Actual Maintenance Treatment
Improvement of Fibrosis (Yes/ no) Defined as at Least One Stage Decrease in Fibrosis Stage After 48 Weeks of Treatment Assessed by Liver Biopsy - Actual Maintenance Treatment30.134.844.221.5
Statistical analysis
  • Survodutide 2.4 mg - Actual Maintenance Treatment vs Placebo - Actual Maintenance Treatment · Regression, Logistic · p = 0.1894 (The p-value reported is considered nominal.) · Odds ratio (or): 1.61 · 95% CI 0.79 to 3.26Survodutide 2.4 mg vs. Placebo
  • Survodutide 4.8 mg - Actual Maintenance Treatment vs Placebo - Actual Maintenance Treatment · Regression, Logistic · p = 0.0685 (The p-value reported is considered nominal.) · Odds ratio (or): 2.00 · 95% CI 0.95 to 4.20Survodutide 4.8 mg vs. Placebo
  • Survodutide 6.0 mg - Actual Maintenance Treatment vs Placebo - Actual Maintenance Treatment · Regression, Logistic · p = 0.0028 (The p-value reported is considered nominal.) · Odds ratio (or): 3.37 · 95% CI 1.52 to 7.45Survodutide 6.0 mg vs. Placebo
SecondaryImprovement of Fibrosis (Yes/ no) Defined as at Least One Stage Decrease in Fibrosis Stage After 48 Weeks of Treatment Assessed by Liver Biopsy - Planned Maintenance Treatment

Percentage of participants with improvement of liver fibrosis is reported. Improvement of fibrosis was defined as at least one stage decrease in fibrosis stage after 48 weeks of treatment assessed by liver biopsy. The total score for the fibrosis stage ranges from 0 to 4 with higher score indication worsening of the disease and the stages of fibrosis based on their location are the following: * 1A Zone 3, perisinusoidal, delicate; * 1B Zone 3, perisinusoidal, dense; * 1C Portal, periportal only; * 2 Zone 3, perisinusoidal + portal, periportal only; * 3 Bridging fibrosis; * 4 Cirrhosis. For analysis purposes no distinction was made between stages 1A, 1B and 1C.

Time frame:
At baseline and after 48 weeks of treatment.
Reported as:
Number · Percentage of participants
Improvement of Fibrosis (Yes/ no) Defined as at Least One Stage Decrease in Fibrosis Stage After 48 Weeks of Treatment Assessed by Liver Biopsy - Planned Maintenance Treatment
Percentage of participantsSurvodutide 2.4 mg - Planned Maintenance TreatmentSurvodutide 4.8 mg - Planned Maintenance TreatmentSurvodutide 6.0 mg - Planned Maintenance TreatmentPlacebo - Planned Maintenance Treatment
Improvement of Fibrosis (Yes/ no) Defined as at Least One Stage Decrease in Fibrosis Stage After 48 Weeks of Treatment Assessed by Liver Biopsy - Planned Maintenance Treatment34.236.133.821.6
Statistical analysis
  • Survodutide 2.4 mg - Planned Maintenance Treatment vs Placebo - Planned Maintenance Treatment · Regression, Logistic · p = 0.0663 (The p-value reported is considered nominal.) · Odds ratio (or): 2.02 · 95% CI 0.95 to 4.27Survodutide 2.4 mg vs. Placebo
  • Survodutide 4.8 mg - Planned Maintenance Treatment vs Placebo - Planned Maintenance Treatment · Regression, Logistic · p = 0.0672 (The p-value reported is considered nominal.) · Odds ratio (or): 2.01 · 95% CI 0.95 to 4.23Survodutide 4.8 mg vs. Placebo
  • Survodutide 6.0 mg - Planned Maintenance Treatment vs Placebo - Planned Maintenance Treatment · Regression, Logistic · p = 0.0512 (The p-value reported is considered nominal.) · Odds ratio (or): 2.11 · 95% CI 1.00 to 4.46Survodutide 6.0 mg vs. Placebo
SecondaryAbsolute Change From Baseline in NAS After 48 Weeks of Treatment Assessed by Liver Biopsy - Actual Maintenance Treatment

Absolute change from baseline in NAS after 48 weeks of treatment assessed by liver biopsy is reported. The non-alcoholic fatty liver disease (NAFLD) activity score (NAS) represents the sum of subscores for steatosis (scored from 0-3), lobular inflammation (scored from 0-3) and ballooning (scored from 0-2), and the total score ranges from 0 to 8 with higher scores representing worsening of the disease.

Time frame:
At baseline and 48 weeks of treatment.
Reported as:
Mean · units on a scale
Absolute Change From Baseline in NAS After 48 Weeks of Treatment Assessed by Liver Biopsy - Actual Maintenance Treatment
units on a scaleSurvodutide 2.4 mg - Actual Maintenance TreatmentSurvodutide 4.8 mg - Actual Maintenance TreatmentSurvodutide 6.0 mg - Actual Maintenance TreatmentPlacebo - Actual Maintenance Treatment
Absolute Change From Baseline in NAS After 48 Weeks of Treatment Assessed by Liver Biopsy - Actual Maintenance Treatment-2.8 ± 1.8-3.2 ± 1.8-3.3 ± 2.0-0.4 ± 1.6
SecondaryAbsolute Change From Baseline in NAS After 48 Weeks of Treatment Assessed by Liver Biopsy - Planned Maintenance Treatment

Absolute change from baseline in NAS after 48 weeks of treatment assessed by liver biopsy is reported. The non-alcoholic fatty liver disease (NAFLD) activity score (NAS) represents the sum of subscores for steatosis (scored from 0-3), lobular inflammation (scored from 0-3) and ballooning (scored from 0-2), and the total score ranges from 0 to 8 with higher scores representing worsening of the disease.

Time frame:
At baseline and 48 weeks of treatment.
Reported as:
Mean · units on a scale
Absolute Change From Baseline in NAS After 48 Weeks of Treatment Assessed by Liver Biopsy - Planned Maintenance Treatment
units on a scaleSurvodutide 2.4 mg - Planned Maintenance TreatmentSurvodutide 4.8 mg - Planned Maintenance TreatmentSurvodutide 6.0 mg - Planned Maintenance TreatmentPlacebo - Planned Maintenance Treatment
Absolute Change From Baseline in NAS After 48 Weeks of Treatment Assessed by Liver Biopsy - Planned Maintenance Treatment-2.8 ± 1.8-3.2 ± 1.8-3.3 ± 1.9-0.2 ± 1.5

Adverse events

Collected over [All-Cause Mortality], [Serious Adverse Events], [Other Adverse Events]: From first study drug administration until last study drug administration plus 28 days of residual effect period (REP), up to 365 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Survodutide 2.4 mg - Actual Maintenance Treatment0/93 (0%)5/93 (5.4%)85/93 (91.4%)
Survodutide 4.8 mg - Actual Maintenance Treatment0/69 (0%)7/69 (10.1%)60/69 (87%)
Survodutide 6.0 mg - Actual Maintenance Treatment0/52 (0%)5/52 (9.6%)49/52 (94.2%)
Placebo - Actual Maintenance Treatment0/79 (0%)5/79 (6.3%)68/79 (86.1%)
Most frequent serious events
Showing 10 of 31
Most frequent serious events
EventSurvodutide 2.4 mg - Actual Maintenance TreatmentSurvodutide 4.8 mg - Actual Maintenance TreatmentSurvodutide 6.0 mg - Actual Maintenance TreatmentPlacebo - Actual Maintenance Treatment
CholelithiasisHepatobiliary disorders0/930/692/520/79
Hepatic cirrhosisHepatobiliary disorders0/930/691/521/79
Amylase increasedInvestigations0/930/691/520/79
Blood creatinine increasedInvestigations0/930/691/520/79
Glomerular filtration rate decreasedInvestigations0/930/691/520/79
Lipase increasedInvestigations0/930/691/520/79
DehydrationMetabolism and nutrition disorders0/930/691/520/79
NephrolithiasisRenal and urinary disorders0/931/691/520/79
Acute myocardial infarctionCardiac disorders0/931/690/520/79
Sudden hearing lossEar and labyrinth disorders0/931/690/520/79
Most frequent other events
Showing 10 of 42
Most frequent other events
EventSurvodutide 2.4 mg - Actual Maintenance TreatmentSurvodutide 4.8 mg - Actual Maintenance TreatmentSurvodutide 6.0 mg - Actual Maintenance TreatmentPlacebo - Actual Maintenance Treatment
NauseaGastrointestinal disorders60/9346/6933/5222/79
DiarrhoeaGastrointestinal disorders38/9337/6929/5220/79
VomitingGastrointestinal disorders38/9333/6915/526/79
ConstipationGastrointestinal disorders16/9312/6915/5214/79
HeadacheNervous system disorders21/9312/696/5213/79
COVID-19Infections and infestations19/9315/695/5216/79
Decreased appetiteMetabolism and nutrition disorders20/939/698/528/79
DyspepsiaGastrointestinal disorders14/936/6911/523/79
FatigueGeneral disorders18/9310/698/527/79
NasopharyngitisInfections and infestations6/9312/694/5210/79

Baseline characteristics

Treated set - planned maintenance treatment: included all patients that were administered survodutide or placebo matching survodutide. Patients are analyzed according to the planned treatment (planned maintenance dose strength) they were assigned at randomisation even if patients did not reach the maintenance period at all, and therefore did not "settle" on any maintenance dose.

Age, Continuous
Age, Continuous(years)Survodutide 2.4 mg - Planned Maintenance TreatmentSurvodutide 4.8 mg - Planned Maintenance TreatmentSurvodutide 6.0 mg - Planned Maintenance TreatmentPlacebo - Planned Maintenance TreatmentTotal
Mean49.6 ± 13.750.2 ± 12.950.4 ± 13.153.0 ± 11.550.8 ± 12.8
Sex: Female, Male
Sex: Female, Male(Participants)Survodutide 2.4 mg - Planned Maintenance TreatmentSurvodutide 4.8 mg - Planned Maintenance TreatmentSurvodutide 6.0 mg - Planned Maintenance TreatmentPlacebo - Planned Maintenance TreatmentTotal
Female36344144155
Male37383330138
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Survodutide 2.4 mg - Planned Maintenance TreatmentSurvodutide 4.8 mg - Planned Maintenance TreatmentSurvodutide 6.0 mg - Planned Maintenance TreatmentPlacebo - Planned Maintenance TreatmentTotal
Hispanic or Latino1419262281
Not Hispanic or Latino59534852212
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Survodutide 2.4 mg - Planned Maintenance TreatmentSurvodutide 4.8 mg - Planned Maintenance TreatmentSurvodutide 6.0 mg - Planned Maintenance TreatmentPlacebo - Planned Maintenance TreatmentTotal
American Indian or Alaska Native00101
Asian2422171780
Native Hawaiian or Other Pacific Islander00011
Black or African American23005
White46475656205
More than one race10001
Unknown or Not Reported00000
NAS score at baseline
NAS score at baseline(score on a scale)Survodutide 2.4 mg - Planned Maintenance TreatmentSurvodutide 4.8 mg - Planned Maintenance TreatmentSurvodutide 6.0 mg - Planned Maintenance TreatmentPlacebo - Planned Maintenance TreatmentTotal
Mean5.2 ± 1.05.3 ± 1.15.1 ± 1.05.2 ± 1.15.2 ± 1.0
Number of participants at each category of liver fibrosis stage at baseline
Number of participants at each category of liver fibrosis stage at baseline(Participants)Survodutide 2.4 mg - Planned Maintenance TreatmentSurvodutide 4.8 mg - Planned Maintenance TreatmentSurvodutide 6.0 mg - Planned Maintenance TreatmentPlacebo - Planned Maintenance TreatmentTotal
Stage 1A03328
Stage 1B17714947
Stage 1C336315
Stage 230362430120
Stage 323232730103
Number of participants in each category of diabetes at baseline
Number of participants in each category of diabetes at baseline(Participants)Survodutide 2.4 mg - Planned Maintenance TreatmentSurvodutide 4.8 mg - Planned Maintenance TreatmentSurvodutide 6.0 mg - Planned Maintenance TreatmentPlacebo - Planned Maintenance TreatmentTotal
No44434445176
Yes29293029117
Number of patients in each category of NAS score
Number of patients in each category of NAS score(Participants)Survodutide 2.4 mg - Planned Maintenance TreatmentSurvodutide 4.8 mg - Planned Maintenance TreatmentSurvodutide 6.0 mg - Planned Maintenance TreatmentPlacebo - Planned Maintenance TreatmentTotal
000000
100000
200000
300000
42120262289
52721172893
6172226873
78851637
801001

2 further baseline measures are reported on the registry.

08

Study locations

154 sites
  • North Alabama Health Research, LLC
    Huntsville, Alabama 35801, United States
  • Southern California Research Center
    Coronado, California 92118, United States
  • Velocity Clinical Research
    Huntington Park, California 90255, United States
  • Velocity Clinical Research
    Panorama City, California 91402, United States
  • Quest Clinical Research
    San Francisco, California 94115, United States
  • Peak Gastroenterology Associates
    Colorado Springs, Colorado 80907, United States
  • Integrity Clinical Research, LLC
    Doral, Florida 33166, United States
  • Covenant Metabolic Specialists, LLC
    Fort Myers, Florida 33912, United States
  • Optimus U Corporation
    Miami, Florida 33135, United States
  • Sanchez Clinical Research ,Inc
    Miami, Florida 33157, United States
  • Ocala GI Research
    Ocala, Florida 34471, United States
  • Omega Research Orlando, LLC
    Orlando, Florida 32808, United States
  • Covenant Metabolic Specialists, LLC
    Sarasota, Florida 34240, United States
  • Gastrointestinal Specialists of Georgia
    Marietta, Georgia 30060, United States
  • Digestive Research Alliance of Michiana
    South Bend, Indiana 46635, United States
  • University of Iowa Hospitals and Clinics
    Iowa City, Iowa 52242, United States
  • Delta Research Partners, LLC
    Bastrop, Louisiana 71220, United States
  • Centex Studies, Inc.
    Lake Charles, Louisiana 70601, United States
  • Tandem Clinical Research
    Marrero, Louisiana 70072, United States
  • NECCR PrimaCare Research, LLC
    Fall River, Massachusetts 02721, United States
  • National Diabetes and Obesity Research Institute
    Biloxi, Mississippi 39532, United States
  • Gastrointestinal Associates
    Flowood, Mississippi 39232, United States
  • AIG Digestive Disease Research
    Florham Park, New Jersey 07932, United States
  • Northeast GI Research Division
    Concord, North Carolina 28027, United States
  • Lucas Research, Inc.
    Morehead City, North Carolina 28557, United States
  • Digestive Diseases Research Center
    Greenwood, South Carolina 29646, United States
  • Palmetto Clinical Research
    Summerville, South Carolina 29485, United States
  • Digestive Health Research, LLC
    Hermitage, Tennessee 37076, United States
  • Texas Clinical Research Institute, LLC
    Arlington, Texas 76012, United States
  • Texas Liver Institute
    Austin, Texas 78757, United States
  • South Texas Research Institute
    Brownsville, Texas 78520, United States
  • South Texas Research Institute
    Edinburg, Texas 78539, United States
  • Houston Methodist Hospital
    Houston, Texas 77030, United States
  • American Research Corporation at the Texas Liver Institute
    San Antonio, Texas 78215, United States
  • Pinnacle Clinical Research
    San Antonio, Texas 78229, United States
  • Virginia Commonwealth University
    Richmond, Virginia 23298, United States
  • Gold Coast University Hospital
    Southport, Queensland 4215, Australia
  • Monash Medical Centre
    Clayton, Victoria 3168, Australia
  • Royal Melbourne Hospital
    Parkville, Victoria 3050, Australia
  • Medical University of Graz State Hospital - University Hospital Graz
    Graz, 8036, Austria
  • Medical University of Innsbruck
    Innsbruck, A-6020, Austria
  • Ordensklinikum Linz GmbH - Barmherzige Schwestern
    Linz, A-4010, Austria
  • Edegem - UNIV UZ Antwerpen
    Edegem, 2650, Belgium
  • University Hospital (LHSC)
    London, Ontario N6A 5A5, Canada
  • Toronto Liver Centre
    Toronto, Ontario M6H 3M1, Canada
  • Ecogene-21
    Chicoutimi, Quebec G7H 7K9, Canada
  • Beijing Ditan Hospital Capital Medical University
    Beijing, 100015, China
  • Beijing Tsinghua Changgung Hospital
    Beijing, 100044, China
  • Peking University People's Hospital
    Beijing, 100044, China
  • Beijing Friendship Hospital
    Beijing, 100050, China
  • The First Hospital of Jilin University
    Changchun, 130021, China
  • The First Afiliated Hospital, Sun Yet-sen University
    Guangzhou, 510080, China
  • NanFang Hosptial
    Guangzhou, 510515, China
  • Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine
    Hangzhou, 310016, China
  • First People's hospital of Yunann Province
    Kunming, 650032, China
  • The Second Hospital of Nanjing
    Nanjing, 210003, China
  • Shanghai Public Health Clinical Center
    Shanghai, 201508, China
  • Tianjin Third Central Hospital
    Tianjin, 300170, China
  • The First Affiliated Hospital of Wenzhou Med College
    Wenxzhou, 325000, China
  • Regional Hospital Liberec
    Liberec, 460 63, Czechia
  • General Faculty Hospital, Prague
    Prague, 128 08, Czechia
  • HOP l'Archet
    Nice, 06200, France
  • HOP La Pitié Salpêtrière
    Paris, 75651, France
  • HOP Haut-Lévêque
    Pessac, 33604, France
  • HOP Civil
    Strasbourg, 67091, France
  • Universitätsklinikum Aachen, AöR
    Aachen, 52074, Germany
  • Synexus Clinical Research GmbH
    Berlin, 12627, Germany
  • Universitätsklinikum Knappschaftskrankenhaus Bochum GmbH
    Bochum, 44892, Germany
  • Universitätsklinikum Düsseldorf
    Düsseldorf, 40225, Germany
  • Synexus Clinical Research GmbH
    Frankfurt, 60313, Germany
  • Synexus Clinical Research GmbH
    Leipzig, 04103, Germany
  • Universitätsmedizin der Johannes Gutenberg-Universität Mainz
    Mainz, 55131, Germany
  • Universitätsklinikum Mannheim GmbH
    Mannheim, 68167, Germany
  • Universitätsklinikum Ulm
    Ulm, 89081, Germany
  • Attikon University Hospital
    Haidari-Athens, 12462, Greece
  • General Hospital of Thessaloniki "Hippokrateio"
    Thessaloniki, 54642, Greece
  • Prince of Wales Hospital
    Hong Kong, 999077, Hong Kong
  • Queen Mary Hospital
    Hong Kong, 999077, Hong Kong
  • Synexus Hungary Healthcare Service Ltd.
    Budapest, 1036, Hungary
  • Fed.St. Istvan&Szent Laszlo Hospital
    Budapest, 1097, Hungary
  • Synexus Hungary Healthcare Service Ltd
    Gyula, 5700, Hungary
  • Shaare Zedek Medical Center, Jerusalem 91031
    Jerusalem, 9103102, Israel
  • Western Galilee Hospital
    Nahariya, 22100, Israel
  • Rabin Medical Center Beilinson
    Petach Tikva, 49100, Israel
  • Sourasky Medical Center
    Tel Aviv, 64239, Israel
  • The Chaim Sheba Medical Center
    Tel-Hashomer, 5265601, Israel
  • Ospedale Civile di Baggiovara
    Baggiovara (MO), 41126, Italy
  • A.O. Univ. Policlinico "Paolo Giaccone"
    Palermo, 90127, Italy
  • Poli Univ A. Gemelli
    Roma, 00195, Italy
  • Istituto Clinico Humanitas
    Rozzano (MI), 20089, Italy
  • IRCCS Ospedale "Casa Sollievo della Sofferenza"
    SAN Giovanni Rotondo (FG), 71013, Italy
  • AO Città della Salute e Scienza
    Torino, 10126, Italy
  • Ehime University Hospital
    Ehime, Toon, 791-0295, Japan
  • Fukuiken Saiseikai Hospital
    Fukui, Fukui, 918-8503, Japan
  • Kurume University Hospital
    Fukuoka, Kurume, 830-0011, Japan
  • Ogaki Municipal Hospital
    Gifu, Ogaki, 503-8502, Japan
  • Japan Community Health Care Organization Hokkaido Hospital
    Hokkaido, Sapporo, 062-8618, Japan
  • Kagawa University Hospital
    Kagawa, Kita-gun, 761-0793, Japan
  • Kagawa Prefectural Central Hospital
    Kagawa, Takamatsu, 760-8557, Japan
  • St. Marianna University Hospital
    Kanagawa, Kawasaki, 216-8511, Japan

Showing the first 100 of 154 sites across 25 countries. Choose a country and city above to see the rest.

09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Also, Researchers can use the following link https://www.mystudywindow.com/msw/datasharing to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website. The data shared are the raw clinical study data sets.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.

Access criteria: For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.

Data sharing details ↗ · www.mystudywindow.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2021 to primary completion in Nov 2023, 30 months.

Results were first posted in Dec 2024, 1 year after primary completion.

Of 132 industry-sponsored phase 2 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's 30 months is above that.

Counting every sponsor, half of 185 studies reached it within 26 months; a quarter within 16 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2021
First posted
Feb 25, 2021
StartActual
Apr 27, 2021
Primary completionActual
Nov 9, 2023
CompletionActual
Dec 21, 2023
Results first posted
Dec 3, 2024
Last update
Dec 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04771273
Responsible party
Sponsor
First posted
Feb 25, 2021
Start date
Apr 27, 2021
Primary completion
Nov 9, 2023
Completion
Dec 21, 2023
Results posted
Dec 3, 2024
Last update
Dec 3, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Survodutide

Start the discussion